clinical trials
-
VSA to Acquire HopeAI, Expanding into AI in Life Science
TCTM Kids IT Education Inc. (VSA) announced a non-binding LOI to acquire HopeAI, a leader in AI solutions for clinical development. This move aims to expand VSA’s presence in the AI-driven biopharmaceutical sector. HopeAI’s platforms offer solutions to reduce clinical trial timelines and improve efficiency. The acquisition is subject to customary closing conditions and will allow VSA to leverage HopeAI’s technology to advance drug development.
-
DATROWAY® Shows Continued Promising Tumor Response in Combination Regimens for Early and Advanced NSCLC
The TROPION-Lung02 and TROPION-Lung04 trials support DATROWAY (datopotamab deruxtecan) combined with immunotherapy as a first-line treatment for advanced NSCLC. TROPION-Lung02 showed a 54.8% objective response rate with DATROWAY and pembrolizumab. Exploratory analyses show promising biomarker associations and the TROPION-Lung04 study found a 57.5% objective response rate when using DATROWAY with rilvegostomig. NeoCOAST-2 data also revealed positive results in the neoadjuvant setting.
